OraSure Technologies (OSUR) Reaches New 1-Year Low at $12.50

Share on StockTwits

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) hit a new 52-week low during trading on Thursday . The company traded as low as $12.50 and last traded at $13.05, with a volume of 47086 shares changing hands. The stock had previously closed at $14.72.

A number of analysts have recently commented on the company. Stephens lowered OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. Zacks Investment Research lowered OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. TheStreet upgraded OraSure Technologies from a “c+” rating to a “b” rating in a report on Thursday, August 9th. BidaskClub lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.50.

The stock has a market cap of $900.47 million, a PE ratio of 25.51, a PEG ratio of 3.46 and a beta of 1.52.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $45.90 million for the quarter, compared to the consensus estimate of $44.50 million. OraSure Technologies had a return on equity of 6.68% and a net margin of 9.49%. OraSure Technologies’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.09 earnings per share. On average, equities analysts forecast that OraSure Technologies, Inc. will post 0.34 EPS for the current year.

In related news, Director Charles W. Patrick sold 8,000 shares of OraSure Technologies stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $16.29, for a total value of $130,320.00. Following the sale, the director now owns 54,298 shares of the company’s stock, valued at $884,514.42. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.90% of the stock is currently owned by insiders.

Several large investors have recently added to or reduced their stakes in OSUR. Point72 Asset Management L.P. acquired a new position in OraSure Technologies during the second quarter worth approximately $122,000. Cubist Systematic Strategies LLC acquired a new position in OraSure Technologies during the first quarter worth approximately $139,000. Campbell & CO Investment Adviser LLC acquired a new position in OraSure Technologies during the third quarter worth approximately $187,000. Oppenheimer Asset Management Inc. acquired a new position in OraSure Technologies during the third quarter worth approximately $194,000. Finally, Engineers Gate Manager LP acquired a new position in OraSure Technologies during the second quarter worth approximately $197,000. 92.00% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “OraSure Technologies (OSUR) Reaches New 1-Year Low at $12.50” was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://weekherald.com/2018/11/10/orasure-technologies-osur-reaches-new-1-year-low-at-12-50.html.

About OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Recommended Story: The Discount Rate – What You Need to Know

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply